ArticleBMC cancer2025
Body composition and immunotherapy outcomes in patients with advanced urothelial carcinoma.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prognostic implications of body composition changes in patients with non-metastatic pancreatic adenocarcinoma treated with mFOLFIRINOX.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundAbnormal body composition is associated with outcomes in patients receiving immune checkpoint inhibitors (ICIs), but its prognostic significance in advanced urothelial carcinoma (aUC) remains unclear. This study investigated the association between computed tomography (CT)-based body composition metrics and clinical outcomes in this population.
methodsPatients with aUC treated with atezolizumab or pembrolizumab between January 2019 and December 2022 at our institution were retrospectively analysed. Body composition was assessed using abdomen–pelvis CT at the L3 vertebral level using artificial intelligence-based platform. Sarcopenia and myosteatosis were defined by T-scores below − 2.0. Visceral obesity (VO) was defined as visceral fat area ≥ 100 cm²; subcutaneous fat obesity (SFO) as subcutaneous fat area/height² ≥50 cm²/m² in men and 42 cm²/m² in women. Associations with overall survival (OS) and progression-free survival (PFS) were evaluated.
resultsAmong 212 patients (median age, 68 years; 75.0% male), 82.0% received atezolizumab and 18.0% pembrolizumab. Sarcopenia and myosteatosis were present in 11.3% and 51.9%; VO and SFO in 61.3% and 42.0%. Sarcopenia and myosteatosis at baseline were significantly associated with shorter OS (HR 2.08; 95% CI, 1.31–3.29; P = 0.002 and HR 1.54; 95% CI 1.14–2.07; P = 0.004, respectively). In multivariable analysis, age < 70, haemoglobin < 10 g/dL, liver metastasis, sarcopenia (HR 2.26; 95% CI, 1.39–3.71; P = 0.001) and myosteatosis (HR 1.49; 95% CI, 1.06–2.01; P = 0.015) were independently associated with OS. Risk stratification based on the presence of sarcopenia and myosteatosis identified the highest mortality risk among patients with sarcopenia alone (HR 3.58; P < 0.001), followed by those with both conditions (HR 2.15, P = 0.015) and myosteatosis alone (HR 1.60, P = 0.003), as compared with patients with neither condition. A model including sarcopenia and myosteatosis yielded modest discrimination (Harrell’s C-index, 0.601), which was improved with the addition of liver metastasis and hemoglobin level (Harrell’s C-index, 0.708). No body composition metric was associated with PFS.
conclusionSarcopenia and myosteatosis were significant independent prognostic factors for OS in ICI-treated aUC patients. Routine CT-based body composition analysis may support risk stratification and guide early interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.